強迫性障害治療薬の世界市場レポート：動向、予測、競合分析（～2031年）

世界の強迫性障害治療薬市場の将来性は、病院、在宅医療、診療所市場での機会により有望視されています。世界の強迫性障害治療薬の市場規模は、2025年～2031年にCAGR7.3%で成長すると予想されます。この市場の主な促進要因は、強迫性障害に対する認識の高まりと精神疾患の罹患率の上昇です。

• Lucintelの予測では、タイプ別では抗うつ薬が予測期間中に最も高い成長を遂げる見込みです。
• 用途別では、病院が最も高い成長が見込まれます。
• 地域別では、アジア太平洋が予測期間中に最も高い成長が見込まれます。

強迫性障害治療薬市場の新たな動向

強迫性障害治療薬市場は、治療効果と患者アクセスの向上を目指す新たな動向の出現により急速に進化しています。医薬品治療、デジタルヘルスツール、統合ケアモデルの進歩が強迫性障害治療の未来を形成しています。これらの動向は、患者の転帰を改善し、ケアの質を向上させるための有望な道筋を示しています。

• 新しい薬理学的治療の使用：OCDをより効果的に治療するために新しい薬剤が導入されています。最近、治療抵抗性OCDの治療薬として承認されたエスケタミンのような薬剤は、SSRIに反応しない患者に新しいアプローチを提供しています。これらの治療薬は、第二世代抗精神病薬やSNRIのような他の治療薬とともに、特に第一選択薬で大きな改善が見られなかった患者に対する治療の選択肢を増やしています。このように治療法が多様化することで、OCDの管理方法が再構築され、従来の薬物療法に苦しんでいた患者にも希望が見えてきます。
• 認知行動療法（CBT）と薬物療法の統合：OCDの治療において、薬物療法と認知行動療法（CBT）、特に曝露反応妨害法（ERP）を統合する傾向が高まっています。この2つのアプローチを組み合わせることで、薬物療法を単独で行うよりも効果的な結果が得られることが研究で示されています。米国やドイツのような国々のヘルスケア提供者は、薬物療法が症状に対処する一方で、OCDの根本的な原因に対処する役割を認識し、標準的な治療プロトコルの一部としてCBTを取り入れています。
• デジタルヘルスツールと遠隔医療：デジタルツールと遠隔医療はOCDの治療方法に革命をもたらしています。モバイルアプリ、バーチャルCBTプログラム、オンラインセラピーセッションにより、患者は遠隔で治療を受けることができ、特に十分な治療を受けていない地域の患者にとって、治療へのアクセスが向上しています。さらに、ウェアラブルデバイスが開発され、症状を追跡し、リアルタイムのフィードバックを提供することで、より良いOCDの管理を可能にしています。これらの技術は、患者とヘルスケア提供者の間のギャップを埋め、継続的なモニタリングとサポートを確実にするのに役立っています。
• 個別化医療への注目：個別化医療はOCD治療において重要な動向となりつつあります。遺伝的、生物学的、心理学的要因を分析することで、ヘルスケア提供者は患者一人一人に合わせた治療計画を立てています。個別化アプローチは、個々の患者が様々な薬にどのように反応するかを考慮し、より的確な治療と有効性の向上を保証するものです。このアプローチは、標準的な薬物療法に反応しない治療抵抗性OCDの場合に特に有効です。
• 認知度の向上と偏見の軽減：OCDを含むメンタルヘルスの問題に対する認識が高まるにつれ、OCDにまつわる偏見は大幅に減少しています。この変化により、より多くの人々が治療を受けるようになり、OCD治療薬の市場も拡大しています。政府のイニシアチブ、非営利団体、メディアによるキャンペーンは、OCDに対する社会的理解の向上に努め、早期診断や治療法へのアクセスの改善に繋がっています。

このような新たな動向は、より効果的で、個別化され、利用しやすい治療を提供することで、OCD治療薬市場を変革しつつあります。新薬の開発、デジタルヘルスツールの開発、統合されたケアモデルの開発により、OCD治療の状況はより患者中心になりつつあり、OCDに苦しむ人々により良い機会を提供しています。

強迫性障害治療薬市場における最近の発展

近年、強迫性障害治療薬市場ではいくつかの重要な発展が見られ、患者に提供される治療の選択肢が向上しています。これらの発展には、新薬の承認、治療技術の進歩、治療へのアクセスの向上などが含まれ、これらすべてが患者の転帰改善に寄与しています。

• 治療抵抗性OCDに対するエスケタミンの承認：治療抵抗性OCD患者に対する治療薬としてエスケタミンが承認されたことは、OCD治療薬市場における大きな進展です。エスケタミンは点鼻スプレーで投与され、従来のSSRIやその他の第一選択治療薬に反応しない患者に代替薬を提供します。今回の承認は、重症のOCD治療における新たな可能性を開くものであり、利用可能な治療選択肢における大きなギャップを解決するものです。
• 個別化治療の進歩：個別化医療はOCD治療にも導入されつつあります。遺伝やこれまでの治療効果、併存障害などを考慮することで、ヘルスケア提供者はよりオーダーメイドの治療計画を提供することができます。個別化されたアプローチは、従来の薬物療法が有効でない治療抵抗性OCDに特に有効です。この動向は治療成果を向上させ、患者の試行錯誤を減らすことが期待されます。
• デジタルヘルスソリューションの成長：症状を管理するアプリやバーチャルCBTプログラムなどのデジタルヘルスツールは、OCDの治療へのアクセスを拡大しています。これらのツールは、患者が遠隔でサポートを受けることを可能にし、対面での治療が困難な患者にとって便利で効果的な選択肢を提供します。この開発は、メンタルヘルスのサービスが制限されている地方や恵まれない地域に住む人々にとって特に有益です。
• 新しい薬物療法の登場：第二世代の抗精神病薬であるアリピプラゾールのような新しい薬理学的選択肢の導入は、OCDの治療法を拡大しました。これらの薬剤は一般的にSSRIと併用され、OCDの症状、特に重症例においてその軽減が期待されています。このような新しい選択肢の開発により、医師は様々なOCD患者を治療するための手段を増やすことになります。
• メンタルヘルスサービスへのアクセスの改善：精神医療サービスに対する意識の高まりと改善への努力により、世界中でOCD治療へのアクセスが向上しています。政府やヘルスケア機関は、資金提供、保険適用範囲の拡大、より多くのメンタルヘルスの専門家の育成を行うことで、治療への障壁を減らす努力をしています。このような治療へのアクセスの向上は、OCDの治療を希望する患者の増加に対応するために不可欠なものです。

これらの主な発展により、患者はOCDの効果的な治療法を見つけやすくなっています。新薬の導入、個人に合わせた治療戦略、デジタルヘルスソリューションにより、患者の選択肢は以前よりも増えています。このような開発により、OCD患者の予後は改善し、治療へのアクセスも拡大しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 背景と分類
• サプライチェーン

第3章 市場動向と予測分析

• マクロ経済の動向と予測
• 業界の促進要因と課題
• PESTLE分析
• 特許分析
• 規制環境

第4章 世界の強迫性障害治療薬市場：タイプ別

• 概要
• タイプ別の魅力分析
• NMDA受容体遮断薬：動向と予測（2019～2031年）
• 抗精神病薬：動向と予測（2019～2031年）
• 抗うつ薬：動向と予測（2019～2031年）

第5章 世界の強迫性障害治療薬市場：用途別

• 概要
• 用途別魅力分析
• 病院：動向と予測（2019～2031年）
• 在宅医療：動向と予測（2019～2031年）
• 診療所：動向と予測（2019～2031年）
• その他：動向と予測（2019～2031年）

第6章 地域分析

• 概要
• 世界の強迫性障害治療薬市場：地域別

第7章 北米の強迫性障害治療薬市場

• 概要
• 北米の強迫性障害治療薬市場（タイプ別）
• 北米の強迫性障害治療薬市場（用途別）
• 米国の強迫性障害治療薬市場
• メキシコの強迫性障害治療薬市場
• カナダの強迫性障害治療薬市場

第8章 欧州の強迫性障害治療薬市場

• 概要
• 欧州の強迫性障害治療薬市場（タイプ別）
• 欧州の強迫性障害治療薬市場（用途別）
• ドイツの強迫性障害治療薬市場
• フランスの強迫性障害治療薬市場
• スペインの強迫性障害治療薬市場
• イタリアの強迫性障害治療薬市場
• 英国の強迫性障害治療薬市場

第9章 アジア太平洋の強迫性障害治療薬市場

• 概要
• アジア太平洋の強迫性障害治療薬市場（タイプ別）
• アジア太平洋の強迫性障害治療薬市場（用途別）
• 日本の強迫性障害治療薬市場
• インドの強迫性障害治療薬市場
• 中国の強迫性障害治療薬市場
• 韓国の強迫性障害治療薬市場
• インドネシアの強迫性障害治療薬市場

第10章 世界のその他地域の強迫性障害治療薬市場

• 概要
• 世界のその他地域の強迫性障害治療薬市場（タイプ別）
• 世界のその他地域の強迫性障害治療薬市場（用途別）
• 中東の強迫性障害治療薬市場
• 南米の強迫性障害治療薬市場
• アフリカの強迫性障害治療薬市場

第11章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析
  • 競争企業間の敵対関係
  • 買い手の交渉力
  • 供給企業の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
• 市場シェア分析

第12章 機会と戦略分析

• バリューチェーン分析
• 成長機会分析
  • タイプ別の成長機会
  • 用途別の成長機会
• 世界の強迫性障害治療薬市場における新たな動向
• 戦略分析
  • 新製品開発
  • 認証とライセンシング
  • 合併、買収、契約、提携、合弁事業

第13章 バリューチェーンにおける主要企業プロファイル

• 競合分析
• Sun Pharmaceuticals Industry
• H.Lunderbeck A/S
• Eli Lilly And Company
• Apotex
• Viatris
• Lannett
• GlaxoSmithKline
• Alvogen
• Pfizer
• Amneal Pharmaceuticals

第14章 付録

• 図一覧
• 表一覧
• 調査手法
• 免責事項
• 著作権
• 略語および技術単位
• Lucintelについて
• お問い合わせ

List of Figures

• Figure 1.1: Trends and Forecast for the Global Obsessive-Compulsive Disorder Medicine Market
• Figure 2.1: Usage of Obsessive-Compulsive Disorder Medicine Market
• Figure 2.2: Classification of the Global Obsessive-Compulsive Disorder Medicine Market
• Figure 2.3: Supply Chain of the Global Obsessive-Compulsive Disorder Medicine Market
• Figure 2.4: Driver and Challenges of the Obsessive-Compulsive Disorder Medicine Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 4.1: Global Obsessive-Compulsive Disorder Medicine Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Obsessive-Compulsive Disorder Medicine Market ($B) by Type
• Figure 4.3: Forecast for the Global Obsessive-Compulsive Disorder Medicine Market ($B) by Type
• Figure 4.4: Trends and Forecast for NMDA Receptor Blockers in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 4.5: Trends and Forecast for Antipsychotics in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 4.6: Trends and Forecast for Antidepressants in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 5.1: Global Obsessive-Compulsive Disorder Medicine Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Obsessive-Compulsive Disorder Medicine Market ($B) by Application
• Figure 5.3: Forecast for the Global Obsessive-Compulsive Disorder Medicine Market ($B) by Application
• Figure 5.4: Trends and Forecast for Hospitals in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 5.5: Trends and Forecast for Homecare in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 5.6: Trends and Forecast for Clinics in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 5.7: Trends and Forecast for Others in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 6.1: Trends of the Global Obsessive-Compulsive Disorder Medicine Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Obsessive-Compulsive Disorder Medicine Market ($B) by Region (2025-2031)
• Figure 7.1: Trends and Forecast for the North American Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 7.2: North American Obsessive-Compulsive Disorder Medicine Market by Type in 2019, 2024, and 2031
• Figure 7.3: Trends of the North American Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2019-2024)
• Figure 7.4: Forecast for the North American Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2025-2031)
• Figure 7.5: North American Obsessive-Compulsive Disorder Medicine Market by Application in 2019, 2024, and 2031
• Figure 7.6: Trends of the North American Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2019-2024)
• Figure 7.7: Forecast for the North American Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2025-2031)
• Figure 7.8: Trends and Forecast for the United States Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Mexican Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 7.10: Trends and Forecast for the Canadian Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 8.1: Trends and Forecast for the European Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 8.2: European Obsessive-Compulsive Disorder Medicine Market by Type in 2019, 2024, and 2031
• Figure 8.3: Trends of the European Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2019-2024)
• Figure 8.4: Forecast for the European Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2025-2031)
• Figure 8.5: European Obsessive-Compulsive Disorder Medicine Market by Application in 2019, 2024, and 2031
• Figure 8.6: Trends of the European Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2019-2024)
• Figure 8.7: Forecast for the European Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2025-2031)
• Figure 8.8: Trends and Forecast for the German Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the French Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Spanish Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the Italian Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 8.12: Trends and Forecast for the United Kingdom Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 9.1: Trends and Forecast for the APAC Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 9.2: APAC Obsessive-Compulsive Disorder Medicine Market by Type in 2019, 2024, and 2031
• Figure 9.3: Trends of the APAC Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2019-2024)
• Figure 9.4: Forecast for the APAC Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2025-2031)
• Figure 9.5: APAC Obsessive-Compulsive Disorder Medicine Market by Application in 2019, 2024, and 2031
• Figure 9.6: Trends of the APAC Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2019-2024)
• Figure 9.7: Forecast for the APAC Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2025-2031)
• Figure 9.8: Trends and Forecast for the Japanese Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Indian Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the Chinese Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the South Korean Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 9.12: Trends and Forecast for the Indonesian Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 10.1: Trends and Forecast for the ROW Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Figure 10.2: ROW Obsessive-Compulsive Disorder Medicine Market by Type in 2019, 2024, and 2031
• Figure 10.3: Trends of the ROW Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2019-2024)
• Figure 10.4: Forecast for the ROW Obsessive-Compulsive Disorder Medicine Market ($B) by Type (2025-2031)
• Figure 10.5: ROW Obsessive-Compulsive Disorder Medicine Market by Application in 2019, 2024, and 2031
• Figure 10.6: Trends of the ROW Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2019-2024)
• Figure 10.7: Forecast for the ROW Obsessive-Compulsive Disorder Medicine Market ($B) by Application (2025-2031)
• Figure 10.8: Trends and Forecast for the Middle Eastern Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the South American Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 10.10: Trends and Forecast for the African Obsessive-Compulsive Disorder Medicine Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Obsessive-Compulsive Disorder Medicine Market
• Figure 11.2: Market Share (%) of Top Players in the Global Obsessive-Compulsive Disorder Medicine Market (2024)
• Figure 12.1: Growth Opportunities for the Global Obsessive-Compulsive Disorder Medicine Market by Type
• Figure 12.2: Growth Opportunities for the Global Obsessive-Compulsive Disorder Medicine Market by Application
• Figure 12.3: Growth Opportunities for the Global Obsessive-Compulsive Disorder Medicine Market by Region
• Figure 12.4: Emerging Trends in the Global Obsessive-Compulsive Disorder Medicine Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Obsessive-Compulsive Disorder Medicine Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Obsessive-Compulsive Disorder Medicine Market by Region
• Table 1.3: Global Obsessive-Compulsive Disorder Medicine Market Parameters and Attributes
• Table 3.1: Trends of the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 3.2: Forecast for the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Obsessive-Compulsive Disorder Medicine Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 4.4: Trends of NMDA Receptor Blockers in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 4.5: Forecast for NMDA Receptor Blockers in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 4.6: Trends of Antipsychotics in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 4.7: Forecast for Antipsychotics in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 4.8: Trends of Antidepressants in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 4.9: Forecast for Antidepressants in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Obsessive-Compulsive Disorder Medicine Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 5.4: Trends of Hospitals in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 5.5: Forecast for Hospitals in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 5.6: Trends of Homecare in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 5.7: Forecast for Homecare in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 5.8: Trends of Clinics in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 5.9: Forecast for Clinics in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 5.10: Trends of Others in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 5.11: Forecast for Others in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 7.1: Trends of the North American Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 7.2: Forecast for the North American Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 8.1: Trends of the European Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 8.2: Forecast for the European Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 9.1: Trends of the APAC Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 9.2: Forecast for the APAC Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 10.1: Trends of the ROW Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 10.2: Forecast for the ROW Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Obsessive-Compulsive Disorder Medicine Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Obsessive-Compulsive Disorder Medicine Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Obsessive-Compulsive Disorder Medicine Market (2019-2031)
• Table 11.1: Product Mapping of Obsessive-Compulsive Disorder Medicine Suppliers Based on Segments
• Table 11.2: Operational Integration of Obsessive-Compulsive Disorder Medicine Manufacturers
• Table 11.3: Rankings of Suppliers Based on Obsessive-Compulsive Disorder Medicine Revenue
• Table 12.1: New Product Launches by Major Obsessive-Compulsive Disorder Medicine Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Obsessive-Compulsive Disorder Medicine Market

The future of the global obsessive-compulsive disorder medicine market looks promising with opportunities in the hospitals, homecare, and clinics markets. The global obsessive-compulsive disorder medicine market is expected to grow with a CAGR of 7.3% from 2025 to 2031. The major drivers for this market are the increasing awareness of OCD and the rising incidence of mental health conditions.

• Lucintel forecasts that, within the type category, antidepressants are expected to witness the highest growth over the forecast period.
• Within the application category, hospitals are expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Obsessive-Compulsive Disorder Medicine Market

The obsessive-compulsive disorder medicine market is evolving rapidly with the emergence of new trends that aim to improve treatment efficacy and patient access. Advances in pharmaceutical therapies, digital health tools, and integrated care models are shaping the future of OCD treatment. These trends offer promising avenues for improving patient outcomes and enhancing the quality of care.

• Use of Novel Pharmacological Treatments: New medications are being introduced to target OCD more effectively. Drugs such as esketamine, which was recently approved for treatment-resistant OCD, are offering a new approach for patients who do not respond to SSRIs. These medications, along with others like second-generation antipsychotics and SNRIs, are improving treatment options, especially for individuals who have not seen significant improvement with first-line therapies. This growing variety of treatments is reshaping how OCD is managed and offers hope for patients who have struggled with traditional medications.
• Integration of Cognitive Behavioral Therapy (CBT) with Medications: A growing trend in the treatment of OCD is the integration of pharmacological treatments with cognitive behavioral therapy (CBT), particularly exposure and response prevention (ERP). Studies have shown that combining these two approaches leads to more effective outcomes than using medications alone. Healthcare providers in countries like the U.S. and Germany are incorporating CBT as part of the standard treatment protocol, recognizing its role in addressing the root causes of OCD while medications manage the symptoms.
• Digital Health Tools and Telemedicine: Digital tools and telemedicine are revolutionizing the way OCD is treated. Mobile apps, virtual CBT programs, and online therapy sessions allow patients to access treatment remotely, improving access to care, especially for those in underserved areas. In addition, wearable devices are being developed to track symptoms, providing real-time feedback and enabling better management of OCD. These technologies are helping to bridge the gap between patients and healthcare providers, ensuring continuous monitoring and support.
• Focus on Personalized Medicine: Personalized medicine is becoming a key trend in OCD treatment. By analyzing genetic, biological, and psychological factors, healthcare providers are developing more customized treatment plans for each patient. Personalized approaches consider how individual patients respond to various medications, ensuring more precise treatment and improving efficacy. This approach is particularly useful in cases of treatment-resistant OCD, where patients have not responded well to standard medications.
• Increase in Awareness and Reduced Stigma: As awareness of mental health issues increases, including OCD, there has been a significant reduction in the stigma surrounding the condition. This shift is encouraging more people to seek treatment, thereby expanding the market for OCD medicines. Government initiatives, non-profit organizations, and media campaigns are working to improve public understanding of OCD, leading to better early diagnosis and improved access to treatment options.

These emerging trends are transforming the OCD medicine market by offering more effective, personalized, and accessible treatments. With the development of novel drugs, digital health tools, and integrated care models, the landscape of OCD treatment is becoming more patient-centric, providing better opportunities for those living with the disorder.

Recent Developments in the Obsessive-Compulsive Disorder Medicine Market

The obsessive-compulsive disorder medicine market has witnessed several key developments in recent years that are improving the treatment options available to patients. These developments include new drug approvals, advancements in therapy techniques, and increased access to care, all of which contribute to better patient outcomes.

• Approval of Esketamine for Treatment-Resistant OCD: The approval of esketamine as a treatment for patients with treatment-resistant OCD represents a major development in the OCD medicine market. Esketamine, delivered via a nasal spray, offers an alternative for patients who have not responded to traditional SSRIs and other first-line treatments. This approval opens up new possibilities for treating severe cases of OCD and addresses a significant gap in the available treatment options.
• Advances in Personalized Treatment Approaches: Personalized medicine is making its way into the OCD treatment landscape. By considering factors like genetics, previous treatment responses, and co-occurring disorders, healthcare providers can offer more tailored treatment plans. Personalized approaches are particularly beneficial for treatment-resistant OCD, where traditional medications may not be effective. This trend is expected to enhance treatment outcomes and reduce the trial-and-error process for patients.
• Growth of Digital Health Solutions: Digital health tools, such as apps for managing symptoms and virtual CBT programs, are expanding access to treatment for OCD. These tools allow patients to receive support remotely, offering a convenient and effective alternative for those who may not have easy access to in-person therapy. This development is particularly beneficial for individuals in rural or underserved areas, where mental health services may be limited.
• Emergence of New Drug Options: The introduction of new pharmacological options like aripiprazole, a second-generation antipsychotic, has expanded the available treatments for OCD. These drugs are typically used in combination with SSRIs and have shown promise in reducing OCD symptoms, particularly in patients with severe cases. The development of these new options provides doctors with more tools to treat patients with different forms of OCD.
• Improved Access to Mental Health Services: Increased awareness and efforts to improve mental health services are resulting in better access to OCD treatments worldwide. Governments and healthcare organizations are working to reduce barriers to care by providing funding, expanding insurance coverage, and training more mental health professionals. This increased access is essential for addressing the growing number of individuals seeking treatment for OCD.

These key developments are making it easier for patients to find effective treatments for OCD. With the introduction of new medications, personalized treatment strategies, and digital health solutions, patients have more options than ever before. These developments are improving overall outcomes for OCD patients and expanding access to care.

Strategic Growth Opportunities in the Obsessive-Compulsive Disorder Medicine Market

The obsessive-compulsive disorder medicine market presents numerous growth opportunities driven by innovations in treatment options, increasing patient awareness, and improvements in healthcare infrastructure. Companies in the market have the chance to capitalize on these opportunities by focusing on unmet needs and expanding access to effective treatments.

• Expanding Digital Health Solutions: Digital health solutions, including apps for symptom tracking, virtual therapy sessions, and wearable devices, represent a key growth opportunity. These tools are becoming increasingly popular for managing OCD, especially in remote areas. Companies that develop or invest in digital health platforms can tap into the growing demand for accessible and cost-effective treatment options.
• Introduction of Combination Therapies: Combination therapies that integrate pharmacological treatments with cognitive behavioral therapy (CBT) are gaining traction. This integrated approach is particularly effective for individuals with severe or treatment-resistant OCD. Companies that focus on developing and marketing these combination therapies can address a significant unmet need in the market, providing more comprehensive care.
• Personalized Medicine and Biomarker Development: Personalized medicine is a growing trend in mental health treatment, including OCD. Developing biomarkers to predict treatment responses and guide personalized treatment strategies presents a valuable growth opportunity. Companies that focus on this area can develop tailored therapies that are more effective, reducing the trial-and-error approach currently prevalent in OCD treatment.
• Expanding Access to Care in Emerging Markets: The OCD medicine market is poised for significant growth in emerging markets, particularly in Asia and Latin America. Increased awareness of mental health issues and improved healthcare infrastructure are driving demand for mental health treatments in these regions. Companies that focus on providing affordable and effective OCD treatments will benefit from this expanding market.
• Focus on New Drug Development: The continued development of new drugs, including fast-acting medications and those for treatment-resistant OCD, presents a substantial growth opportunity. With regulatory agencies approving more innovative treatments, pharmaceutical companies can expand their product portfolios, improving patient outcomes and capturing larger market shares.

These growth opportunities are expected to drive significant advancements in the OCD medicine market. Companies that capitalize on these trends will help shape the future of OCD treatment by offering more accessible, personalized, and effective solutions to patients worldwide.

Obsessive-Compulsive Disorder Medicine Market Driver and Challenges

The obsessive-compulsive disorder medicine market is influenced by a combination of drivers and challenges, including technological advancements, increasing patient demand, and regulatory hurdles. Understanding these factors is essential for navigating the market and developing effective solutions for OCD.

The factors responsible for driving the obsessive-compulsive disorder medicine market include:

1. Advancements in Drug Development: Continued innovation in the development of new medications for OCD is a major driver of market growth. New drugs, including esketamine and aripiprazole, are offering more treatment options for patients, particularly those with treatment-resistant OCD.

2. Increasing Awareness of Mental Health: Growing awareness of mental health issues is leading to better recognition and diagnosis of OCD. As more people understand the symptoms of OCD, the demand for effective treatments is rising, driving market growth.

3. Improvements in Healthcare Access: Expanding healthcare infrastructure, particularly in emerging markets, is improving access to OCD treatments. As more people seek care, the market for OCD medications continues to grow.

4. Shift Toward Personalized Medicine: Personalized medicine is becoming a key trend in OCD treatment, with healthcare providers tailoring therapies to individual patient needs. This shift is driving demand for customized treatment options and improving outcomes.

5. Government Support for Mental Health: Governments worldwide are increasing funding for mental health programs, including those focused on OCD. These initiatives are helping to improve diagnosis, treatment access, and awareness, contributing to market growth.

Challenges in the obsessive-compulsive disorder medicine market are:

1. High Treatment Costs: The cost of new medications, especially biologics and combination therapies, is a significant challenge for patients, especially in lower-income regions. High treatment costs limit access to care and hinder market expansion.

2. Limited Availability of Specialized Care: In many regions, there is a lack of specialized care for OCD, including trained therapists and access to advanced treatments. This creates barriers for patients seeking effective care, limiting the market's potential.

3. Stigma Around Mental Health: Despite increased awareness, the stigma surrounding mental health conditions like OCD persists in certain cultures. This stigma can prevent individuals from seeking treatment, limiting the growth of the OCD medicine market.

The OCD medicine market is growing due to advancements in treatment options, increased awareness, and improving healthcare access. However, challenges like high costs, limited specialized care, and stigma remain significant barriers. Addressing these challenges will be crucial for unlocking the full potential of the market.

List of Obsessive-Compulsive Disorder Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, obsessive-compulsive disorder medicine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the obsessive-compulsive disorder medicine companies profiled in this report include:

• Sun Pharmaceuticals Industry
• H. Lunderbeck A/S
• Eli Lilly and Company
• Apotex
• Viatris
• Lannett
• GlaxoSmithKline
• Alvogen
• Pfizer
• Amneal Pharmaceuticals

Obsessive-Compulsive Disorder Medicine Market by Segment

The study includes a forecast for the global obsessive-compulsive disorder medicine market by type, application, and region.

Obsessive-Compulsive Disorder Medicine Market by Type [Value from 2019 to 2031]:

• NMDA Receptor Blockers
• Antipsychotics
• Antidepressants

Obsessive-Compulsive Disorder Medicine Market by Application [Value from 2019 to 2031]:

• Hospitals
• Homecare
• Clinics
• Others

Obsessive-Compulsive Disorder Medicine Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Obsessive-Compulsive Disorder Medicine Market

Obsessive-compulsive disorder medicine market is a chronic mental health condition marked by persistent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions). The global OCD medicine market has evolved with new medications and therapies aimed at improving the quality of life for individuals suffering from this condition. Significant advancements have been made in pharmacological treatments, including selective serotonin reuptake inhibitors (SSRIs) and new generation drugs. Additionally, growing awareness of mental health and increasing availability of personalized treatments are accelerating market growth. The United States, China, Germany, India, and Japan have each seen unique developments in the OCD medicine market that cater to both the rising demand and the need for better treatment solutions.

• United States: In the United States, the OCD medicine market has seen a surge in demand, driven by increased awareness and more advanced treatment options. Recent approvals of medications like esketamine (a nasal spray for treatment-resistant OCD) have introduced new avenues for patients who do not respond to traditional SSRIs. Cognitive behavioral therapy (CBT) integrated with pharmaceutical treatments continues to be the gold standard in treating OCD. The market is also witnessing a rise in research focusing on novel drug formulations, as well as the development of digital tools like apps for monitoring symptoms and enhancing treatment adherence.
• China: China is making strides in expanding its OCD medicine market as mental health issues gain recognition. Traditional SSRIs are the first-line treatment in the country, though the introduction of newer drugs such as clomipramine and serotonin-norepinephrine reuptake inhibitors (SNRIs) is slowly changing the landscape. The Chinese government has been investing in improving mental health services and access to medications, but the treatment for OCD is still in its early stages compared to Western nations. Cultural factors also affect how OCD is perceived and diagnosed, influencing market growth in the region.
• Germany: Germany has one of the most well-established healthcare systems in Europe and is a leader in the development and approval of new treatments for OCD. The use of SSRIs such as fluoxetine and sertraline remains widespread, but more specialized medications like selective serotonin-norepinephrine reuptake inhibitors (SSNRIs) are increasingly used. Additionally, the country is investing in research on gene therapy and novel psychiatric treatments. Germany's healthcare providers also incorporate cognitive behavioral therapy (CBT) as a complementary treatment alongside medications, a dual approach that has improved outcomes for many patients suffering from OCD.
• India: In India, the OCD medicine market is evolving, though it faces challenges due to limited access to newer medications and mental health treatments. SSRIs like fluoxetine are commonly prescribed, but newer treatments are often less accessible due to cost and availability. However, awareness of mental health conditions, including OCD, is increasing due to educational campaigns and government initiatives. India is beginning to explore the integration of pharmacological treatments with digital tools, such as telemedicine and mobile health apps, to improve diagnosis and treatment adherence in rural areas.
• Japan: The Japanese OCD medicine market has been shaped by the integration of advanced psychiatric treatments with traditional practices. SSRIs remain the cornerstone of treatment in Japan, though newer drugs like aripiprazole and esketamine are gaining traction, especially for treatment-resistant cases. The country also emphasizes a holistic approach that combines medication with cognitive behavioral therapy. With Japan's well-developed healthcare infrastructure, patients have better access to cutting-edge treatments. Additionally, Japan's government has been investing in mental health awareness programs, helping to reduce the stigma associated with OCD and increasing demand for medical solutions.

Features of the Global Obsessive-Compulsive Disorder Medicine Market

• Market Size Estimates: Obsessive-compulsive disorder medicine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Obsessive-compulsive disorder medicine market size by type, application, and region in terms of value ($B).
• Regional Analysis: Obsessive-compulsive disorder medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the obsessive-compulsive disorder medicine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the obsessive-compulsive disorder medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the obsessive-compulsive disorder medicine market by type (NMDA receptor blockers, antipsychotics, and antidepressants), application (hospitals, homecare, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Obsessive-Compulsive Disorder Medicine Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 NMDA Receptor Blockers: Trends and Forecast (2019-2031)
• 4.4 Antipsychotics: Trends and Forecast (2019-2031)
• 4.5 Antidepressants: Trends and Forecast (2019-2031)

5. Global Obsessive-Compulsive Disorder Medicine Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Homecare: Trends and Forecast (2019-2031)
• 5.5 Clinics: Trends and Forecast (2019-2031)
• 5.6 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Obsessive-Compulsive Disorder Medicine Market by Region

7. North American Obsessive-Compulsive Disorder Medicine Market

• 7.1 Overview
• 7.2 North American Obsessive-Compulsive Disorder Medicine Market by Type
• 7.3 North American Obsessive-Compulsive Disorder Medicine Market by Application
• 7.4 United States Obsessive-Compulsive Disorder Medicine Market
• 7.5 Mexican Obsessive-Compulsive Disorder Medicine Market
• 7.6 Canadian Obsessive-Compulsive Disorder Medicine Market

8. European Obsessive-Compulsive Disorder Medicine Market

• 8.1 Overview
• 8.2 European Obsessive-Compulsive Disorder Medicine Market by Type
• 8.3 European Obsessive-Compulsive Disorder Medicine Market by Application
• 8.4 German Obsessive-Compulsive Disorder Medicine Market
• 8.5 French Obsessive-Compulsive Disorder Medicine Market
• 8.6 Spanish Obsessive-Compulsive Disorder Medicine Market
• 8.7 Italian Obsessive-Compulsive Disorder Medicine Market
• 8.8 United Kingdom Obsessive-Compulsive Disorder Medicine Market

9. APAC Obsessive-Compulsive Disorder Medicine Market

• 9.1 Overview
• 9.2 APAC Obsessive-Compulsive Disorder Medicine Market by Type
• 9.3 APAC Obsessive-Compulsive Disorder Medicine Market by Application
• 9.4 Japanese Obsessive-Compulsive Disorder Medicine Market
• 9.5 Indian Obsessive-Compulsive Disorder Medicine Market
• 9.6 Chinese Obsessive-Compulsive Disorder Medicine Market
• 9.7 South Korean Obsessive-Compulsive Disorder Medicine Market
• 9.8 Indonesian Obsessive-Compulsive Disorder Medicine Market

10. ROW Obsessive-Compulsive Disorder Medicine Market

• 10.1 Overview
• 10.2 ROW Obsessive-Compulsive Disorder Medicine Market by Type
• 10.3 ROW Obsessive-Compulsive Disorder Medicine Market by Application
• 10.4 Middle Eastern Obsessive-Compulsive Disorder Medicine Market
• 10.5 South American Obsessive-Compulsive Disorder Medicine Market
• 10.6 African Obsessive-Compulsive Disorder Medicine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Obsessive-Compulsive Disorder Medicine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Sun Pharmaceuticals Industry
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 H.Lunderbeck A/S
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Eli Lilly And Company
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Apotex
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Viatris
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Lannett
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 GlaxoSmithKline
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Alvogen
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Pfizer
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Amneal Pharmaceuticals
  • Company Overview
  • Obsessive-Compulsive Disorder Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us